In previous systematic reviews of advanced esophageal cancer, the overall survival (OS) for second- and third-line patients using best supportive care (BSC) was typically around 3-4 months. The use of single-agent chemotherapy (such as docetaxel or irinotecan) or targeted therapy (regorafenib) extended OS by 1.1-1.4 months.
晚期食管癌治疗新进展
本文基于2025最新系统综述，解析晚期食管癌二线及三线治疗中最佳支持治疗、单药化疗和靶向治疗的生存期延长效果，提供详细治疗方案对比与疗效分析。
与梅斯小智对话
